Immuno-oncology

Merck's Keytruda wins approval in first-line lung cancer

Merck's Keytruda wins approval in first-line lung cancer

By

Keytruda is the first immuno-oncology drug approved to treat first-line lung cancer.

Five things for pharma marketers to know: Friday, October 14, 2016

Five things for pharma marketers to know: Friday, October 14, 2016

By

Merck launches biosimilar resource; branded insulin prices are on the rise; NICE declines to cover Opdivo

Already ahead in race to first-line approval, could second-line domination be far behind for Keytruda?

Already ahead in race to first-line approval, could second-line domination be far behind for Keytruda?

By

One analyst envisions how a first-line approval could set up Keytruda for success in other settings.

DTC ads for Opdivo face further backlash

DTC ads for Opdivo face further backlash

By

Critics say the direct-to-consumer ad for the immuno-oncology therapy is misleading.

Five things for pharma marketers to know: Tuesday, July 26, 2016

Five things for pharma marketers to know: Tuesday, July 26, 2016

By

Sales of Gilead's HCV drugs fall; the DNC policy platform criticized price gouging; Janssen partners with Bristol-Myers Squibb on Opdivo combo drug

Five things for pharma marketers to know: Friday, June 10, 2016

Five things for pharma marketers to know: Friday, June 10, 2016

By

FDA leader says drugmakers should develop more novel drugs; Merck to acquire Afferent for $1.25 billion; Colombia demands lower prices for Gleevec

Infographic: Merck's Keytruda versus Bristol-Myers Squibb's Opdivo

Infographic: Merck's Keytruda versus Bristol-Myers Squibb's Opdivo

Here, see side-by-side comparisons of the drugs spending on advertising, approval dates, and 2015 sales figures.

Five things for pharma marketers to know: Wednesday, April 20, 2016

Five things for pharma marketers to know: Wednesday, April 20, 2016

By

Immuno-oncology drugs showing results in hard-to-treat cancers; Express Scripts responds to Anthem lawsuit; BI and Lilly plan outcomes trials for Jardiance

Five things for pharma marketers to know: Friday, April 15, 2016

Five things for pharma marketers to know: Friday, April 15, 2016

By

Bristol-Myers Squibb seeks new indication for Opdivo; Clinton received $2.8 million from the healthcare industry; Quest creates tests for hep.-C drugs

Drugmakers partner in immuno-oncology, to better capture market share

Drugmakers partner in immuno-oncology, to better capture market share

By

Manufacturers team up to study drug combinations, a strategy expected to advance the category.

Five things for pharma marketers to know: Friday, February 19, 2016

Five things for pharma marketers to know: Friday, February 19, 2016

By

Cancer MoonShot 2020 to study childhood cancers; IBM's purchase of Truven provides data about 200 million patients; overdoses tied to benzodiazepines rise

Five things for pharma marketers to know: Monday, January 11, 2016

Five things for pharma marketers to know: Monday, January 11, 2016

By

Shire buys Baxalta, creates world's largest rare-disease drugmaker; drug prices continue to climb; immunotherapy coalition is formed

Five things for pharma marketers to know: Wednesday, December 16, 2015

Five things for pharma marketers to know: Wednesday, December 16, 2015

By

Britain says Bristol-Myers Squibb's Opdivo is too expensive; Calpers reports 32% boost in specialty drug spending; NIH is funding fewer clinical trials

Five things for pharma marketers to know: Tuesday, November 24, 2015

Five things for pharma marketers to know: Tuesday, November 24, 2015

By

Opdivo receives another indication; increasing generic prescriptions may boost patient adherence; hep.-C drugs should be prescribed during earlier stages of disease

Five things for pharma marketers to know: Thursday, October 1, 2015

Five things for pharma marketers to know: Thursday, October 1, 2015

By

The FDA approves Opdivo/Yervoy combination to treat melanoma; BioMarin acquires global rights to Kuvan; Allergan's Juvederm receives marketing approval for lip augmentation

Bristol-Myers Squibb promotes employees

Bristol-Myers Squibb promotes employees

By

The drugmaker launched its first YouTube channel as it kicked off the campaign.

Five things for pharma marketers to know: Thursday, August 27

Five things for pharma marketers to know: Thursday, August 27

By

The FDA releases biosimilar-naming draft guidance; PD1 drugs linked to a rare type of diabetes; Amgen's PCSK9 inhibitor faces approval decision

Merck's Keytruda gains market share in Q2

Merck's Keytruda gains market share in Q2

By

The immuno-oncology drug is competing with Bristol-Myers Squibb's Opdivo.

Five things for pharma marketers to know: Tuesday, July 28

Five things for pharma marketers to know: Tuesday, July 28

By

Sanofi plans immuno-oncology collaboration with Regeneron; Merck considers hard-to-treat patient populations for its experimental hepatitis-C therapy; drugmakers did not report 10% of adverse events to the FDA within required timeframe

OPINION

Email Newsletters